Published in Women's Health Weekly, July 24th, 2003
GBI recently completed a direct licensing agreement with the University of Michigan for the mammastatin technology from which the MSA is derived. The increased control over this technology now affords to GBI the opportunity, subject to adequate financing, to put the development process on a fast track commercialization strategy.
GBI is required to complete certain additional financings in order to complete that anticipated schedule. The company is working to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly